EMVision Medical Devices Ltd Triggers A Milestone Grant Payment

EMVision Medical Devices Ltd (ASX: EMV) has submitted the required documentation to the Australian Stroke Alliance to trigger a further $600,000 non-dilutive milestone grant payment.

The ASA is funded by the Commonwealth of Australia’s Medical Research Future Fund.

The grant is under the AMRF’s “Ambulance Application – validation pilot studies planning initiated.”

EMVision is a medical device company focused on the timely diagnosis and treatment of stroke and other time-sensitive medical emergencies at point-of-care.

Stroke is a global societal and health economic burden. The ability to distinguish stroke type, size, severity, and location, promptly, is crucial to enable successful stroke treatment.

EMVision is bringing imaging to where strokes occur to save lives.

Keysight Technologies Inc.

EMVision recently attracted a strategic A$15.3 million investment from Keysight Technologies Inc (NYSE: KEYS), a long-standing technology collaborator of the company.

Keysight is a global leader in radiofrequency testing and measurement technology, with a portfolio of Vector Network Analysers (VNAs), core to the sensors used in EMVision’s emu™ device point-of-care brain scanner.

The funding injection supports EMVision’s market entry by expanding emu™ production capacity and clinical trial initiatives, including prestigious stroke institutions in the United States.

EMVision and Keysight recently jointly showcased the emu™ device at the Radiological Society of North America, the world’s premier medical imaging conference, generating significant clinical and industry interest throughout the event.

Articles of Interest